I have built Hillman Ventures in Dallas since 1995. Five generations of my family before me. The operating network in Dallas, in healthcare specifically, is deeper, more aligned, more interconnected, and less performative than what I see in the coastal hubs. The data backs up what I see in my daily work. Dallas biotech is quietly becoming a primary hub for FDA-regulated frontier medicine. Most of the country still has not noticed.
The research infrastructure.
UT Southwestern Medical Center is a top-tier academic medical center with multiple Nobel laureates on faculty. Methodist Health System is one of the largest health systems in the country and a sophisticated clinical research partner. UT Dallas runs strong programs in biomedical engineering. SMU has the business school for the entrepreneurial side. Texas A&M Health Science Center adds breadth across the broader region. Scottish Rite for Children adds pediatric depth. UNT Health Science Center adds osteopathic, public health, and forensics depth.
Six major institutions in a sixty-mile radius. The density is real.
The clinical population.
Dallas-Fort Worth is one of the fastest-growing metropolitan areas in the country. The growth pulls in patient populations that match the indications biotech programs are working on. The population diversity makes the trial data more generalizable than data run in some of the smaller homogeneous markets.
The cost structure.
The cost structure in Dallas is meaningfully different from Boston or San Francisco. Lab space, clinical office space, and operating headcount cost a fraction of what they cost in the coastal hubs. A series A budget in Dallas extends meaningfully further than the same budget in Cambridge or South San Francisco. This is not just an early-stage benefit. It compounds across the life of the program because the operating burn rate is structurally lower.
The capital landscape.
Dallas family offices have been quietly investing in healthcare and biotechnology for decades. The scale of activity is increasing. The Texas family office network is large, sophisticated, and increasingly cross-pollinating with the institutional venture community on the coasts. The state's lack of personal income tax has been moving capital from California and New York to Texas for years. Some of that capital is now finding biotech.
The regulatory environment.
The FDA's CBER and CDER do not care whether you operate from Boston or from Dallas. Pre-IND meetings happen on Zoom. INDs are submitted electronically. The biology does not care about the geography. What does matter is the local clinical research infrastructure for running trials, which Dallas-Fort Worth has in spades.
The Texas regulatory landscape for clinical research, ambulatory surgical centers, and specialty pharmacy is supportive of business in ways that some coastal jurisdictions are not. The Texas Medical Board, the Texas Department of State Health Services, and the Texas State Board of Pharmacy are administratively predictable and operationally fair partners.
The operator network.
Three decades of medical device, pharmacy, surgical hospital, and pharmaceutical wholesale operating has built a community of people who have done the work. The community is small enough that everyone knows everyone. Large enough that the talent pool can staff a credible program. Connected enough that introductions and recommendations actually happen.
The coastal hubs have larger talent pools but the density of operator depth in Dallas is unusual.
The trade-offs.
Dallas lacks the concentration of biotech-specific venture capital that Cambridge and South San Francisco have. The local public-market analyst coverage is thinner. The mainstream press coverage of Dallas biotech is sparse. The Boston biotech network effects, twenty-five years deep, are not yet matched.
The verdict.
For founders building FDA-regulated programs and looking for the right place to do it, Dallas deserves a real look. The biotech ecosystem is no longer secondary. It is becoming primary for the kind of patient-capital, milestone-aligned work that defines frontier medicine right now.
If you are evaluating Dallas, the operating network is open. Introductions are short. The work is the same as it would be anywhere, but the support structure makes it materially easier.
Hillman Ventures has been operating here for three decades. The number of operator-investors and family office principals in healthcare in Dallas is small enough to know personally. Reach out if you want introductions to the network.